138 related articles for article (PubMed ID: 34991789)
1. Maternal Cardiac Function at Midgestation and Development of Preeclampsia.
Gibbone E; Huluta I; Wright A; Nicolaides KH; Charakida M
J Am Coll Cardiol; 2022 Jan; 79(1):52-62. PubMed ID: 34991789
[TBL] [Abstract][Full Text] [Related]
2. Placental function and fetal weight are associated with maternal hemodynamic indices in uncomplicated pregnancies at 35-37 weeks of gestation.
Garcia-Gonzalez C; Abdel-Azim S; Galeva S; Georgiopoulos G; Nicolaides KH; Charakida M
Am J Obstet Gynecol; 2020 Jun; 222(6):604.e1-604.e10. PubMed ID: 31954157
[TBL] [Abstract][Full Text] [Related]
3. Maternal vascular indices at 36 weeks' gestation in the prediction of preeclampsia.
Mansukhani T; Wright A; Arechvo A; Lamanna B; Menezes M; Nicolaides KH; Charakida M
Am J Obstet Gynecol; 2024 Apr; 230(4):448.e1-448.e15. PubMed ID: 37778678
[TBL] [Abstract][Full Text] [Related]
4. Maternal cardiac function at 19-23 weeks' gestation in prediction of pre-eclampsia.
Gibbone E; Wright A; Vallenas Campos R; Sanchez Sierra A; Nicolaides KH; Charakida M
Ultrasound Obstet Gynecol; 2021 May; 57(5):739-747. PubMed ID: 33294998
[TBL] [Abstract][Full Text] [Related]
5. Fetal cardiac function at 35-37 weeks' gestation in pregnancies that subsequently develop pre-eclampsia.
Semmler J; Garcia-Gonzalez C; Sanchez Sierra A; Gallardo Arozena M; Nicolaides KH; Charakida M
Ultrasound Obstet Gynecol; 2021 Mar; 57(3):417-422. PubMed ID: 33098138
[TBL] [Abstract][Full Text] [Related]
6. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
[TBL] [Abstract][Full Text] [Related]
7. Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
[TBL] [Abstract][Full Text] [Related]
8. Screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu A; Ciobanu A; Syngelaki A; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Oct; 52(4):501-506. PubMed ID: 29896778
[TBL] [Abstract][Full Text] [Related]
9. Midgestation cardiovascular phenotype in women who develop gestational diabetes and hypertensive disorders of pregnancy: comparative study.
Anzoategui S; Gibbone E; Wright A; Nicolaides KH; Charakida M
Ultrasound Obstet Gynecol; 2022 Aug; 60(2):207-214. PubMed ID: 35502146
[TBL] [Abstract][Full Text] [Related]
10. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
[TBL] [Abstract][Full Text] [Related]
11. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
Litwinska M; Litwinska E; Astudillo A; Syngelaki A; Wright A; Nicolaides KH
Ultrasound Obstet Gynecol; 2021 Sep; 58(3):360-368. PubMed ID: 33794058
[TBL] [Abstract][Full Text] [Related]
12. Uterine and fetal placental Doppler indices are associated with maternal cardiovascular function.
Tay J; Masini G; McEniery CM; Giussani DA; Shaw CJ; Wilkinson IB; Bennett PR; Lees CC
Am J Obstet Gynecol; 2019 Jan; 220(1):96.e1-96.e8. PubMed ID: 30243605
[TBL] [Abstract][Full Text] [Related]
13. Fetal Cardiac Function at Midgestation and Subsequent Development of Preeclampsia.
Huluta I; Wright A; Cosma LM; Hamed K; Nicolaides KH; Charakida M
J Am Soc Echocardiogr; 2023 Oct; 36(10):1110-1115. PubMed ID: 37230422
[TBL] [Abstract][Full Text] [Related]
14. Maternal hemodynamics in screen-positive and screen-negative women of the ASPRE trial.
Ling HZ; Guy GP; Bisquera A; Poon LC; Nicolaides KH; Kametas NA
Ultrasound Obstet Gynecol; 2019 Jul; 54(1):51-57. PubMed ID: 30246326
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
[TBL] [Abstract][Full Text] [Related]
17. Maternal cardiac parameters can help in differentiating the clinical profile of preeclampsia and in predicting progression from mild to severe forms.
Di Pasquo E; Ghi T; Dall'Asta A; Angeli L; Fieni S; Pedrazzi G; Frusca T
Am J Obstet Gynecol; 2019 Dec; 221(6):633.e1-633.e9. PubMed ID: 31226294
[TBL] [Abstract][Full Text] [Related]
18. Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe preeclampsia.
Woodham PC; Brittain JE; Baker AM; Long DL; Haeri S; Camargo CA; Boggess KA; Stuebe AM
Hypertension; 2011 Dec; 58(6):1120-5. PubMed ID: 21986503
[TBL] [Abstract][Full Text] [Related]
19. Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S; Silva M; Wright A; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Jul; 48(1):72-9. PubMed ID: 26566592
[TBL] [Abstract][Full Text] [Related]
20. STATIN trial: predictive performance of competing-risks model in screening for pre-eclampsia at 35-37 weeks' gestation.
Döbert M; Wright A; Varouxaki AN; Mu AC; Syngelaki A; Rehal A; Delgado JL; Akolekar R; Muscettola G; Janga D; Singh M; Martin-Alonso R; Dütemeyer V; De Alvarado M; Atanasova V; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2022 Jan; 59(1):69-75. PubMed ID: 34580947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
